Literature DB >> 3897468

Echovirus meningomyeloencephalitis with administration of intrathecal immunoglobulin.

M G Hadfield, M Seidlin, S A Houff, C F Adair, S M Markowitz, S E Straus.   

Abstract

Echovirus meningomyeloencephalitis was treated with cerebral intraventricular immunoglobulin. This case includes a complete examination of the central nervous system (CNS) supported by viral culture studies, immunoperoxidase staining and electron microscopy. Neuronal loss was most severe in the cerebellum and spinal cord. This may lead to the ataxia and a poliomyelitis-like syndrome often seen in cases of echovirus meningomyeloencephalitis. Focal encephalitic lesions, antigen-antibody reactions and live virus were found at numerous levels of the CNS in spite of intrathecal and intravenous immunoglobulin therapy. This mode of therapy and the electron microscopic features noted in echovirus infections are discussed.

Entities:  

Mesh:

Year:  1985        PMID: 3897468     DOI: 10.1097/00005072-198509000-00007

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  4 in total

Review 1.  New and old aspects of immunoglobulin application. The use of intravenous IgG as prophylaxis and for treatment of infections.

Authors:  L Hammarström; C I Smith
Journal:  Infection       Date:  1990 Sep-Oct       Impact factor: 3.553

2.  Failure of intraventricular gammaglobulin and alpha interferon for persistent encephalitis in congenital hypogammaglobulinaemia.

Authors:  D M Roberton; I Jack; W Joshi; F Law; C S Hosking
Journal:  Arch Dis Child       Date:  1988-08       Impact factor: 3.791

3.  Intravitreal human immune globulin in a rabbit model of Staphylococcus aureus toxin-mediated endophthalmitis: a potential adjunct in the treatment of endophthalmitis.

Authors:  Dennis P Han
Journal:  Trans Am Ophthalmol Soc       Date:  2004

Review 4.  Chronic enteroviral meningoencephalitis in agammaglobulinemia: case report and literature review.

Authors:  S A Misbah; G P Spickett; P C Ryba; J M Hockaday; J S Kroll; C Sherwood; J B Kurtz; E R Moxon; H M Chapel
Journal:  J Clin Immunol       Date:  1992-07       Impact factor: 8.317

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.